TSP Capital Management Group’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Hold |
0
| – | – | – | 13 |
|
|
2025
Q4 | – | Sell |
-375,927
| Closed | -$9.9M | – | 17 |
|
|
2025
Q3 | $9.73M | Buy |
+375,927
| New | +$8.71M | 2.6% | 17 |
|
|
2025
Q2 | – | Sell |
-335,977
| Closed | -$6.54M | – | 19 |
|
|
2025
Q1 | $6.1M | Buy |
335,977
+112,634
| +50% | +$2.52M | 2.01% | 21 |
|
|
2024
Q4 | $5.64M | Sell |
223,343
-24,477
| -10% | -$665K | 1.92% | 21 |
|
|
2024
Q3 | $8.42M | Sell |
247,820
-1,400
| -0.6% | -$53.3K | 2.61% | 17 |
|
|
2024
Q2 | $9.22M | Hold |
249,220
| – | – | 2.89% | 18 |
|
|
2024
Q1 | $10.5M | Sell |
249,220
-2,275
| -0.9% | -$93.4K | 3.37% | 14 |
|
|
2023
Q4 | $9.97M | Sell |
251,495
-200
| -0.1% | -$5.88K | 3.46% | 13 |
|
|
2023
Q3 | $6.93M | Sell |
251,695
-200
| -0.1% | -$6.27K | 2.67% | 19 |
|
|
2023
Q2 | $8.55M | Sell |
251,895
-500
| -0.2% | -$16.9K | 3.08% | 17 |
|
|
2023
Q1 | $9.08M | Sell |
252,395
-17,500
| -6% | -$755K | 3.28% | 15 |
|
|
2022
Q4 | $12M | Buy |
+269,895
| New | +$9.64M | 4.5% | 5 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 16 |
|
|
2022
Q2 | – | Hold |
0
| – | – | – | 18 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 17 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 14 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 4 |
|
|
2021
Q2 | – | Sell |
-359,229
| Closed | -$9.86M | – | 10 |
|
|
2021
Q1 | $7.4M | Sell |
359,229
-44,000
| -11% | -$1.01M | 2.61% | 17 |
|
|
2020
Q4 | $7.07M | Buy |
+403,229
| New | +$7.26M | 2.51% | 18 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 19 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 21 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 39 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 42 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 50 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 52 |
|
|
2019
Q1 | – | Sell |
-15,795
| Closed | -$83.1K | – | 43 |
|
|
2018
Q4 | $1.2M | Buy |
+15,795
| New | +$77.6K | 0.67% | 38 |
|
|
2018
Q3 | – | Sell |
-88,547
| Closed | -$620K | – | 35 |
|
|
2018
Q2 | $669K | Sell |
88,547
-7,250
| -8% | -$96.9K | 0.34% | 46 |
|
|
2018
Q1 | $3.35M | Buy |
95,797
+10,593
| +12% | +$410K | 1.6% | 26 |
|
|
2017
Q4 | $3.63M | Buy |
85,204
+7,956
| +10% | +$341K | 1.65% | 22 |
|
|
2017
Q3 | $3.31M | Buy |
+77,248
| New | +$2.9M | 1.58% | 24 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 25 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 23 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 21 |
|
|
2016
Q3 | – | Sell |
-54,565
| Closed | -$3.4M | – | 21 |
|
|
2016
Q2 | $3.59M | Sell |
54,565
-2,497
| -4% | -$159K | 1.86% | 20 |
|
|
2016
Q1 | $3.23M | Buy |
57,062
+1,619
| +3% | +$182K | 1.78% | 21 |
|
|
2015
Q4 | $13M | Buy |
55,443
+464
| +0.8% | +$101K | 6.97% | 1 |
|
|
2015
Q3 | $8.69M | Buy |
54,979
+800
| +1% | +$226K | 4.88% | 2 |
|
|
2015
Q2 | $20.5M | Buy |
+54,179
| New | +$21.5M | 9.53% | 1 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 1 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 1 |
|
|
2014
Q3 | – | Sell |
-54,084
| Closed | -$11.8M | – | 2 |
|
|
2014
Q2 | $13.2M | Buy |
+54,084
| New | +$12.2M | 5.75% | 1 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 1 |
|
|
2013
Q4 | – | Hold |
0
| – | – | – | 1 |
|
|
2013
Q3 | – | Hold |
0
| – | – | – | 1 |
|
|
2013
Q2 | – | Hold |
0
| – | – | – | 1 |
|
Other funds holding CLDX
KCM
VCM
CC
EP
TSP Capital Management Group's CLDX Position: Q1 2026 in Review
TSP Capital Management Group held its Celldex Therapeutics (CLDX) position steady in Q1 2026 at 0 shares worth $11.9M. The position accounts for 2.9% of the portfolio, ranked #13.
TSP Capital Management Group first reported a position in CLDX in Q2 2014 and has held it in 24 quarters since. The position peaked at $20.5M in Q2 2015. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.
- TSP Capital Management Group held 0 shares of Celldex Therapeutics worth $11.9M as of Q1 2026.
- TSP Capital Management Group left its Celldex Therapeutics share count unchanged in Q1 2026.
- Celldex Therapeutics made up 2.9% of TSP Capital Management Group's portfolio in Q1 2026, its #13 holding.
- TSP Capital Management Group first reported a position in Celldex Therapeutics in Q2 2014 and has held it in 24 quarters since.
- TSP Capital Management Group's Celldex Therapeutics position peaked at $20.5M in Q2 2015.
- 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.
Based on TSP Capital Management Group's 13F filing for Q1 2026, filed 24 Apr 2026.